A Sampling of Highlights from the Literature

What We're Reading| September 03 2024 A Sampling of Highlights from the Literature Author & Article Information Online ISSN: 2326-6074 Print ISSN: 2326-6066 ©2024 American Association for Cancer Research2024American Association for Cancer Research Cancer Immunol Res (2024) 12 (9): 1129. https://doi.org/10.1158/2326-6066.CIR-12-9-WWR Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 3 2024 Citation A Sampling of Highlights from the Literature. Cancer Immunol Res 1 September 2024; 12 (9): 1129. https://doi.org/10.1158/2326-6066.CIR-12-9-WWR Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search T cells engineered to express personalized neoantigen-specific TCRs cause tumor regression (from Wikimedia Commons). Different approaches to adoptive cell therapy are being evaluated in various clinical trials. Parkhurst and colleagues report results from a phase 2 clinical trial evaluating autologous peripheral blood lymphocytes (PBLs) genetically modified via retroviral transduction to express neoantigen-reactive T-cell receptors (TCRs) isolated from tumor-infiltrating lymphocytes from the patients. Among the seven patients with metastatic colorectal cancer who were treated, three had short-duration partial responses, as assessed by RECIST 1.1 criteria. The data provide support for further clinical evaluation of T cells genetically modified to express personalized neoantigen-reactive TCRs. Parkhurst M, …, Rosenberg SA. Nat Med 2024 July 11. DOI:10.1038/s41591-024-03109-0. Treg accumulation at peri-lymphatic regions in tumor stroma limits antitumor immunity (from Manu5 via Wikimedia Commons). What makes the tumor microenvironment (TME) immunosuppressive is yet to be completely characterized. To address this knowledge gap,... You do not currently have access to this content.